Lumos Pharma announced that on Thursday, March 14, 2024, the Company received a Notice of Allowance from the US Patent and Trade Office for claims in its patent application number PCT/US22/050700 titled “Compactable Oral Formulations of Ibutamoren.” This patent contains claims directed to certain improved formulations of LUM-201 the Company intends to utilize in its Phase 3 trial and ultimately commercialize. This grant of this novel formulation patent extends intellectual property protection through November 2042 for these improved versions of LUM-201 drug product.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LUMO:
- Lumos Pharma reports Q4 EPS ($1.17), consensus ($1.15)
- Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
- Lumos Pharma, Inc. (LUMO) Q4 Earnings Cheat Sheet
- Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
- Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue